Log In
BCIQ
Print this Print this
 

SRX251

  Manage Alerts
Collapse Summary General Information
Company Azevan Pharmaceuticals Inc.
DescriptionVasopressin 1a (V1a) receptor antagonist
Molecular Target Vasopressin 1a (V1a) receptor
Mechanism of ActionVasopressin 1 (V1) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationShock / trauma
Indication DetailsTreat traumatic brain injury (TBI)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today